Cargando…

Enteral Nutrition during Radiotherapy for Oropharyngeal Cancers: Prevalence and Prognostic Factors Based on HPV Status (A GETTEC Study)

Nutritional support during radiotherapy is crucial to tolerating and completing oropharyngeal squamous cell carcinoma (OPSCC) treatment. The impact of HPV status on nutritional support is debated. The objective was to evaluate the rate of Reactive Feeding Tube (RFT) use and determine its prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Culié, Dorian, Schiappa, Renaud, Pace-Loscos, Tanguy, Guelfucci, Bruno, Vergez, Sebastien, Garrel, Renaud, Fakhry, Nicolas, Dassonville, Olivier, Poissonnet, Gilles, Lallemant, Benjamin, Sudaka, Anne, Saada-Bouzid, Esma, Benezery, Karen, Temam, Stephane, Gorphe, Phillipe, Chamorey, Emmanuel, Bozec, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179627/
https://www.ncbi.nlm.nih.gov/pubmed/37176609
http://dx.doi.org/10.3390/jcm12093169
Descripción
Sumario:Nutritional support during radiotherapy is crucial to tolerating and completing oropharyngeal squamous cell carcinoma (OPSCC) treatment. The impact of HPV status on nutritional support is debated. The objective was to evaluate the rate of Reactive Feeding Tube (RFT) use and determine its prognostic factors during definitive radiotherapy for OPSCC. All OPSCC patients treated from 2009 to 2014 were included in this multicentric retrospective study. The impact of tumor p16 status on the risk of RFT was assessed through multivariate analyses. Among the 543 patients, 103 patients required an RFT (19.0%). The use of RFT differed between centers (5% to 32.4%). In multivariate analysis, only tongue base involvement and concurrent chemotherapy were significantly associated with RFT (OR = 2.18 and 3.7, respectively). Tongue base involvement and concomitant chemotherapy were prognostic factors for RFT. HPV status was not a prognostic factor for enteral nutrition during radiotherapy for OPSCC.